Sarepta Risk and the FDA
Sarepta’s Exondys 51 approval despite a 12-patient trial frames FDA regulatory risk and a call to remove Commissioner Robert Califf.
Tuesday, October 31
Tuesday, October 31, 2023
Everything we published on this day.
1 story
Tuesday, October 31
Everything we published on this day.
1 story
Sarepta’s Exondys 51 approval despite a 12-patient trial frames FDA regulatory risk and a call to remove Commissioner Robert Califf.